Clinical Trials · NCT02229383
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 464
- Start date
- Sep 2014
- Locations
- 123 sites, 6 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 28